RenovoRx (NASDAQ:RNXT) Issues Earnings Results

RenovoRx (NASDAQ:RNXT) posted its earnings results on Monday. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01), reports. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.17 million.

RenovoRx Stock Up 1.0 %

Shares of NASDAQ:RNXT traded up $0.01 during midday trading on Wednesday, reaching $0.97. The company’s stock had a trading volume of 10,440 shares, compared to its average volume of 134,993. RenovoRx has a 12-month low of $0.77 and a 12-month high of $1.69. The firm has a market capitalization of $23.28 million, a P/E ratio of -1.70 and a beta of 1.15. The firm has a 50 day moving average of $1.10 and a 200-day moving average of $1.15.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on RNXT shares. Ascendiant Capital Markets increased their price target on shares of RenovoRx from $8.25 to $9.00 and gave the stock a “buy” rating in a research note on Tuesday, December 10th. HC Wainwright assumed coverage on RenovoRx in a research report on Thursday, March 27th. They issued a “buy” rating and a $3.00 target price for the company.

About RenovoRx

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.